On ‘International Mount Everest Day’ (29th May) ‘The Art Maze’, by Curator Marcus Schaefer, Unveils Artist Sacha Jafri’s Latest Masterpiece as a First Time Ever Event at Mount Everest
31.5.2022 09:00:00 EEST | Business Wire | Press release
‘The Art Maze’ World Tour, in partnership with UNESCO, is an unpresented collection of 50 UNESCO World Heritage Sites, created by celebrated Artist, Sacha Jafri, in celebration of UNESCO World Heritage Site’s 50th year anniversary and The Next 50, a year-long UNESCO campaign promoting interdisciplinary reflection on the future of the World’s Heritage.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220530005345/en/
Jafri's Everest Painting Unveiled (Photo: AETOSWire)
Jafri, awarded by the UN for his humanitarian work raising over $140 million for charitable causes, is unveiling his ‘Sagarmatha National Park - Mount Everest’ painting, a spectacular 380cmx160cm three-canvas Triptych piece. With this project Jafri aims to reconnect humanity to our cultural heritage, our ancestral past and the beauty that surrounds us within our natural world, as well as shine a light on the important conversations and actions so desperately needed for the future of our world, in the areas of equality, sustainability & climate change.
Sacha Jafri, Artist & Philanthropist: “It is such an honour for me to partner with ‘The Art Maze’ and UNESCO using the power of art to reconnect with humanity in space and on earth.”
Marcus Schaefer, Art Visionary & Curator: “Feeling such a strong connection to this great country, we are so excited to unveil Sacha’s latest painting with the people of Nepal at the majestic Mount Everest.”
Michael Croft, Head of Office and Representative to Nepal at UNESCO: “As we listen to communities from the mountain regions and hear their perspective on tackling the dual challenges of climate change and sustainable tourism, we are at once motivated - and better informed - how best to fashion our own actions for change.”
UNESCO’s partnership with ‘The Art Maze’ and Sacha Jafri reinforces its mission of promoting inclusive, interdisciplinary dialogues related to climate change, heritage conservation, sustainable tourism, and the challenges these sites face in the context of climate change. In Nepal, UNESCO is working to bring together mountain community leaders as part of The Next 50 dialogues.
Raza Beig, Chairman of BoredPuma: “So excited to be able to announce my purchase of this monumental painting - I now own a piece of a living Indian master, Sacha Jafri, but also, the artistic expression of the world’s largest natural beauty - Mount Everest.”
In honour of this cause, Jafri is producing a signature print collection for art lovers who are keen to own a piece of his humanitarian journey. They can be found at: https://www.collection.theartmaze.com/
‘The Art Maze’ visits 18 countries across six continents of the world 2022-2024 with the next stop in Paris, September 2022, at UNESCO’s Headquarters commemorating the organisation’s 50th anniversary with all 50 of Jafri’s paintings on display.
Follow ‘The Art Maze’
WEBSITE:
www.theartmaze.com
@sachajafri @the.artmaze
Download Images & Films
HERE
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220530005345/en/
Contact information
Leidar
Lejo Johnny
Lejo.johnny@leidar.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 02:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million milestone payment to Biocytogen. According to IDEAYA, the Phase 1 study is designed to characterize IDE034’s safety profile, tolerability, and PK as a monotherapy, and IDEAYA also intends to evaluate combination regimens with DNA damage response (DDR) -targeting agents such as its oral PARG inhibitor IDE161 as the program advances. IDE034 is a potential first-in-class bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and lice
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 14:00:00 EET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 13:00:00 EET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP) Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 Constraints Not Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. C
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 10:15:00 EET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 09:18:00 EET | Press release
Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers compared to currently available technologies. This in turn is boosting expectations
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom